Table 1.
Epidemiological characteristics of 2022-mpox outbreak.
| Study |
Participants |
HIV-positive |
Specific behaviors |
Age Median (IQR) |
Skin∗ |
Anogenital |
Semen |
Saliva |
|---|---|---|---|---|---|---|---|---|
| MSM | MPXV DNA prevalence | MPXV DNA prevalence | MPXV DNA prevalence | MPXV DNA prevalence | ||||
| European Region (ECDC, 2023) [2] | 25 471 | 3927/10 366 (38 %) | 96 % | 31–40+ | 100 %‡ | NA | NA | NA |
| Spain (Hernaez et al., 2022) [3] | 44 | 23/44 (52 %) | 94 % | 35 (11·3) | NA | NA | NA | 85 % |
| Italy (Agrati et al., 2022) [4] | 17 | 7/17 (41 %) | 100 % | 39·5 (33·5–45·25) | 100 % | NA | NA | NA |
| France (Mailhe et al., 2022) [5] | 264 | 73/256 (29 %) | 95 % | 35 (30–41) | 98 % | NA | NA | NA |
| Spain (Tarín-Vicente et al., 2022) [6] | 181 | 72/181 (40 %) | 92 % | 37 (31–42) | 99 % | 78 % | NA | NA |
| Italy (Raccagni et al., 2022) [7] | 36 | 15/36 (42 %) | 100 % | 34 (29–36.5) | 100 %§ | . | 61 % | NA |
| 15 countries (Angelo et al., 2022)∗∗ [8] | 226 | 92/209 (44 %) | 99 % | 37 (32–43) | 100 % | NA | NA | NA |
| Spain (Peiró-Mestres et al., 2022) [9] | 12 | 4/12 (33 %) | 98 % | 38.5 (32–52) + | 100 % | 92 % | 78 % | 100 % |
| UK (Patel et al., 2022) [10] | 197 | 70/195 (35.9 %) | 99.5 % | 38 | 100 %‡ | NA | NA | NA |
| 16 countries (Thornhill et al., 2022)† [11] | 528 | 218/528 (41 %) | 98 % | 38 (18–69) + | 100 %‡ | . | 91 % | NA |
| Italy (Lapa et al., 2022) [12] | 1 | 1/1 (100 %) | 100 % | 39 | NA | NA | 100 % | NA |
| Germany (Hoffmann et al., 2022) [13] | 546 | 256/546 (47 %) | 100 % | 39 (20–67) + | 100 %‡ | NA | NA | NA |
| Spain (Vivancos-Gallego et al., 2022) [21] | 25 | 25/25 (100 %) | 100 % | 39.5 (33–46) | 91 % | 90 % | NA | NA |
| Portugal (Duque et al., 2022) [14] | 27 | 14/27 (52 %) | 95 % (18/19) | 33 (22–51) | 100 %‡ | NA | NA | NA |
| Spain (Echevarría et al., 2023) [20] | 49 | 15/49 (31 %) | 96 % | 37.6# | 100 %‡ | 80 % | NA | NA |
| USA (Philpott et al., 2022) [15] | 1195 | 136/334 (41 %) | 94 % | 35 (30–41) | 100 %‡ | NA | NA | NA |
| Spain (Iñigo Martínez et al., 2022) [16] | 508 | 225/508 (42 %) | 93 % | 35 (18–67) + | 100 %‡ | NA | NA | NA |
| UK(Girometti, N., et, 2022) [17] | 54 | 13/54 (24 %) | 100 % | 41 (34–45) | 100 %‡ | NA | NA | NA |
| Spain (Orviz, E. et al., 2022) [18] | 48 | 19/48 (40 %) | 87.5 % | 35 (29–44) | 100 %‡ | NA | NA | NA |
| France (Palich et al., 2022) [19] | 50 | 22/50 (44 %) | 98 % | 34 (29–40) | 88 % | 71 % | 54 % | NA |
IQR- Interquartile range.
∗
Includes perianal skin.
†
Argentina, Australia, Belgium, Canada, Denmark, France, Germany, Israel, Italy, Mexico, Portugal, Spain, Switzerland, The Netherlands, UK, and USA.
∗∗
Argentina, Belgium, Canada, Denmark, France, Germany, Israel, Portugal, South Africa, Spain, Sweden, Romania, The Netherlands,UK, and USA.
+
Range in years.
#
Mean age.
‡
Skin or anogenital samples combined.
§
Either skin, anogenital, or oropharyngeal samples combined.